Diabetes, Vol 41, Issue 8 975-981, Copyright © 1992 by American Diabetes Association

ARTICLES

In vitro effects of amylin on carbohydrate metabolism in liver cells

TP Ciaraldi, M Goldberg, R Odom and M Stolpe
Department of Veterans Affairs Medical Center, San Diego, California.

Amylin, a peptide found in pancreatic amyloid deposits, may be involved in NIDDM. The effects of biosynthetic human amylin on multiple aspects of carbohydrate metabolism were studied in freshly isolated and cultured liver cells (rat hepatocytes and HepG2 cells). Acute exposure of culture liver cells to amylin had no effect on glucose incorporation into glycogen. Amylin directly reduced glucose oxidation through the hexose monophosphate shunt. The glycolytic pathway was unaffected. Amylin stimulated both glycogenolysis and gluconeogenesis. These effects were largest at amylin concentrations of 1-10 pM. Insulin partially inhibited both of these responses. Glucagon stimulated glycogenolysis and gluconeogenesis to a similar extent as amylin but required concentrations 100- to 500-fold as high. Thus, amylin, at physiologic concentrations, can impair some aspects of glucose use in liver cells and is also capable of directly stimulating glucose production, suggesting a possible involvement of amylin in the impaired glucose disposal and elevated hepatic glucose output of NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. P. Ciaraldi, L. Carter, S. Nikoulina, S. Mudaliar, D. A. McClain, and R. R. Henry Glucosamine Regulation of Glucose Metabolism in Cultured Human Skeletal Muscle Cells: Divergent Effects on Glucose Transport/Phosphorylation and Glycogen Synthase in Non-Diabetic and Type 2 Diabetic Subjects Endocrinology, September 1, 1999; 140(9): 3971 - 3980. [Abstract] [Full Text]

				T. P. Ciaraldi, L. Carter, S. Mudaliar, P. A. Kern, and R. R. Henry Effects of Tumor Necrosis Factor-{alpha} on Glucose Metabolism in Cultured Human Muscle Cells from Nondiabetic and Type 2 Diabetic Subjects Endocrinology, December 1, 1998; 139(12): 4793 - 4800. [Abstract] [Full Text] [PDF]

				M. Clodi, K. Thomaseth, G. Pacini, K. Hermann, A. Kautzky-Willer, W. Waldhausl, R. Prager, and B. Ludvik Distribution and kinetics of amylin in humans Am J Physiol Endocrinol Metab, May 1, 1998; 274(5): E903 - E908. [Abstract] [Full Text] [PDF]

				D. Maggi, G. Andraghetti, J.-L. Carpentier, and R. Cordera Cys860 in the Extracellular Domain of Insulin Receptor {beta}-Subunit Is Critical for Internalization and Signal Transduction Endocrinology, February 1, 1998; 139(2): 496 - 504. [Abstract] [Full Text] [PDF]

				P. Berhanu, C. Anderson, M. Hickman, and T. P. Ciaraldi Insulin Signal Transduction by a Mutant Human Insulin Receptor Lacking the NPEY Sequence. EVIDENCE FOR AN ALTERNATE MITOGENIC SIGNALING PATHWAY THAT IS INDEPENDENT OF Shc PHOSPHORYLATION J. Biol. Chem., September 5, 1997; 272(36): 22884 - 22890. [Abstract] [Full Text] [PDF]

				J. Permert, J. Larsson, G. T. Westermark, M. K. Herrington, L. Christmanson, P. M. Pour, P. Westermark, and T. E. Adrian Islet Amyloid Polypeptide in Patients with Pancreatic Cancer and Diabetes N. Engl. J. Med., February 3, 1994; 330(5): 313 - 318. [Abstract] [Full Text]